Lakefront Biotherapeutics NV (LKFT) - Total Assets
Based on the latest financial reports, Lakefront Biotherapeutics NV (LKFT) holds total assets worth $3.35 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Lakefront Biotherapeutics NV cash flow conversion for how efficiently the company converts equity into cash flow.
Lakefront Biotherapeutics NV - Total Assets Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's total assets have evolved over time, based on quarterly financial data. See Lakefront Biotherapeutics NV (LKFT) share price today for real-time trading data and today's change.
Lakefront Biotherapeutics NV - Asset Composition Analysis
Current Asset Composition (December 2025)
Lakefront Biotherapeutics NV's total assets of $3.35 Billion consist of 90.4% current assets and 9.6% non-current assets. Explore working capital to net assets of Lakefront Biotherapeutics NV to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.6% |
| Accounts Receivable | $53.20 Million | 1.6% |
| Inventory | $22.49 Million | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $848.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Lakefront Biotherapeutics NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lakefront Biotherapeutics NV's current assets represent 90.4% of total assets in 2025, an increase from 89.5% in 2022.
- Cash Position: Cash and equivalents constituted 2.6% of total assets in 2025, down from 10.7% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 1.6% of total assets.
Lakefront Biotherapeutics NV Competitors by Total Assets
Key competitors of Lakefront Biotherapeutics NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Galecto Inc
NASDAQ:GLTO
|
USA | $535.44 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
ABL Bio Inc
KQ:298380
|
Korea | ₩273.72 Billion |
Lakefront Biotherapeutics NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 32.82 | 8.08 | 7.95 |
| Quick Ratio | 32.70 | 7.99 | 7.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.24 Billion | $2.85 Billion | $3.04 Billion |
Lakefront Biotherapeutics NV - Advanced Valuation Insights
This section examines the relationship between Lakefront Biotherapeutics NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -17.6% |
| Total Assets | $3.41 Billion |
| Market Capitalization | $1.76 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Lakefront Biotherapeutics NV's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lakefront Biotherapeutics NV's assets decreased by 17.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lakefront Biotherapeutics NV (2022–2025)
The table below shows the annual total assets of Lakefront Biotherapeutics NV from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.41 Billion | -17.63% |
| 2024-12-31 | $4.14 Billion | -5.09% |
| 2023-12-31 | $4.36 Billion | -7.96% |
| 2022-12-31 | $4.73 Billion | -- |
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more